Vaccines, Antibodies, Biomarkers and Correlates of Protection
View Presentation *Mark T. Esser, MedImmune, Inc. Keywords: Biomarker Assays Biomarkers have been used historically to monitor disease incidence and prevalence, measure immune responses to natural infection or vaccination and to determine the duration of immunity. This talk will discuss how antibody and functional biomarker assays are being implemented to accelerate phase I vaccine/antibody studies, dose ranging studies, evaluate adjuvants, licensure studies, concomitant vaccine studies, phase IV marketing studies and post-licensure surveillance studies. Specific examples of how biomarkers were used in the development and post-licensure marketing studies of FluMist® and Synagis® will be reviewed.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC